Glaukos Corporation
GKOS
Classement en actions
#2018
Glaukos Corporation operates as an ophthalmic medical technology and... Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
Prix de l'action
$174.03
Dernière synchronisation: 2026-10-20
Capitalisation boursière
$10.26B
Changement (1 jour)
4.34%
Changement (1 an)
129.35%
Pays
US
Échange Glaukos Corporation (GKOS)
Catégorie
Healthcare
Revenus pour Glaukos Corporation (GKOS)
Revenus en Jun 2026 TTM : $612.84M
Selon les derniers rapports financiers de Glaukos Corporation, le chiffre d'affaires actuel de l'entreprise (TTM) est de $612.84M. En 2023, l'entreprise a réalisé un chiffre d'affaires de $314.71M une augmentation par rapport à le chiffre d'affaires de l'année 2022, qui était de $282.86M. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Glaukos Corporation de 2012 à 2026
Revenus à la fin de chaque année
| Année | Revenus | Changez |
|---|---|---|
| 2026 (TTM) | $612.84M | 59.81% |
| 2024 | $383.48M | 21.85% |
| 2023 | $314.71M | 11.26% |
| 2022 | $282.86M | -3.79% |
| 2021 | $294.01M | 30.70% |
| 2020 | $224.96M | -5.07% |
| 2019 | $236.98M | 30.73% |
| 2018 | $181.28M | 13.83% |
| 2017 | $159.25M | 39.21% |
| 2016 | $114.40M | 59.55% |
| 2015 | $71.70M | 57.28% |
| 2014 | $45.59M | 117.64% |
| 2013 | $20.95M | 762.33% |
| 2012 | $2.43M | 0.00% |
Revenus d’entreprises similaires ou concurrentes
| Entreprise | Revenus | Différence de revenus | Pays |
|---|---|---|---|
| $46.59B | 7,501.51% |
US
|
|
| $35.48B | 5,690.10% |
IE
|
|
| $25.84B | 4,115.95% |
US
|
|
| $21.00B | 3,326.02% |
US
|
|
| - | - |
DE
|
